⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419917 | 0.70 | CCR2 (0.31) | — | |
| SCHEMBL37603 | 0.66 | — | — | |
| SCHEMBL16246596 | 0.65 | CCR2 (0.36) | — | |
| SCHEMBL6105380 | 0.62 | — | — | |
| SCHEMBL8688355 | 0.62 | — | — | |
| SCHEMBL5635896 | 0.61 | SRD5A1 (0.33) | — | |
| SCHEMBL9416877 | 0.61 | — | — | |
| SCHEMBL14244063 | 0.61 | — | — | |
| SCHEMBL28230760 | 0.61 | HTR3A (0.35) | — | |
| SCHEMBL27467506 | 0.60 | NISCH (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608648-B1 | PYRIDYLOXYMETHYL AND BENZISOXAZOLE AZABICYCLIC DERIVATIVES | PFIZER PROD INC (US) | 2012-07-18 | — | — | EP | disclosed |
| CN-100389115-C | Pyridyloxymethyl and benziso * azole azabicyclic derivatives | PFIZER (US) | 2008-05-21 | — | — | CN | disclosed |
| US-7345038-B2 | Pyridyloxymethyl and benzisoxazole azabicyclic derivatives | PFIZER, INC (US) | 2008-03-18 | — | — | US | disclosed |
| CN-1759116-A | Pyridyloxymethyl and benzisoxazole azabicyclic derivatives | PFIZER (US) | 2006-04-12 | — | — | CN | disclosed |
| EP-1608648-A1 | PYRIDYLOXYMETHYL AND BENZISOXAZOLE AZABICYCLIC DERIVATIVES | Pfizer Products Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6887905-B2 | Treatment of depression or generalized anxiety disorder | PFIZER INC (US) | 2005-05-03 | — | — | US | disclosed |
| US-20050026922-A1 | For treating CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression; side effect reduction; for example, (7R,9aS)-trans-7-[6-(2,6-Dimethyl-piperidin-1-ylmethyl)-pyridin-2-yloxymethyl]-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine | PFIZER INC | 2005-02-03 | — | — | US | disclosed |
| WO-2004081007-A1 | PYRIDYLOXYMETHYL AND BENZISOXAZOLE AZABICYCLIC DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20030181458-A1 | Azabicyclic 5HT1 receptor ligands | PFIZER INC. | 2003-09-25 | — | — | US | disclosed |
| EP-1070065-B1 | AZABICYCLIC 5HT1 RECEPTOR LIGANDS | PFIZER PROD INC (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6525048-B1 | Aminomethylphenoxymethyl/benzisoxazole substituted azabicyclic compounds; depression, generalized anxiety disorder, obesity, migraine; 2-(5-Fluoro-benzo(d)isoxazol-3-y)-7-(3-morpholin-4-ylmethylphenoxymethyl) -octahydro-pyrido(1,2-a)pyrazine; | PFIZER INC. | 2003-02-25 | — | — | US | disclosed |
| EP-1070065-A1 | AZABICYCLIC 5HT1 RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999052907-A1 | AZABICYCLIC 5HT1 RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 1999-10-21 | — | — | WO | disclosed |